Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Nov;38(6):593-602.
doi: 10.1007/BF02344863.

Iterative optimal design of PET experiments for estimating beta-adrenergic receptor concentration

Affiliations

Iterative optimal design of PET experiments for estimating beta-adrenergic receptor concentration

R F Muzic Jr et al. Med Biol Eng Comput. 2000 Nov.

Abstract

To estimate in vivo myocardial beta-adrenergic receptor concentration with sufficient precision and to reduce the experimental complexities in positron emission tomography (PET), an iterative optimal design method is applied. An initial three-injection protocol, utilising [F-18]-labelled (R)- and (S)-fluorocarazolol and unlabelled (S)-fluorocarazolol, is optimised for ligand dosages and administration times to maximise the precision of all model parameters using the D-optimal criterion. Using this experimental protocol, PET data are collected in porcine studies, and model parameters are estimated. All model parameters are identified with satisfactory precision. The in vivo myocardial beta-receptor concentration is 7.5+/-0.6 pmol x ml(-1), which corresponds to the in vitro result of 10.1+/-1.3 pmol x ml(-1). With more accurate parameter values, a simplified two-injection protocol is optimally designed, utilising only radiolabelled and unlabelled (S)-fluorocarazolol, based on a new criterion to maximise the precision of the beta-receptor concentration. This revised optimum design predicts that the in vivo beta-receptor concentration can be estimated with good precision but reduced experiment complexity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Med Chem. 1994 Sep 30;37(20):3219-30 - PubMed
    1. Nucl Med Biol. 1996 Feb;23(2):159-67 - PubMed
    1. Am J Physiol. 1991 Sep;261(3 Pt 2):H929-49 - PubMed
    1. Phys Med Biol. 1989 Apr;34(4):419-35 - PubMed
    1. J Cardiovasc Pharmacol. 1988;12 Suppl 1:S15-24 - PubMed

Publication types